Ascendis Pharma/$ASND
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Ticker
$ASND
Sector
Primary listing
Employees
1,017
Headquarters
Hellerup, Denmark
Website
Ascendis Pharma Metrics
BasicAdvanced
$12B
-
-$5.28
0.41
-
Price and volume
Market cap
$12B
Beta
0.41
52-week high
$216.45
52-week low
$118.03
Average daily volume
427K
Financial strength
Current ratio
1.019
Quick ratio
0.658
Long term debt to equity
-176.032
Total debt to equity
-422.523
Interest coverage (TTM)
-2.99%
Profitability
EBITDA (TTM)
-287.506
Gross margin (TTM)
84.88%
Net profit margin (TTM)
-55.25%
Operating margin (TTM)
-51.66%
Effective tax rate (TTM)
-2.66%
Revenue per employee (TTM)
$555,110
Management effectiveness
Return on assets (TTM)
-17.17%
Return on equity (TTM)
106.60%
Valuation
Price to revenue (TTM)
20.714
Price to book
-63.84
Price to tangible book (TTM)
-62.57
Price to free cash flow (TTM)
-59.486
Free cash flow yield (TTM)
-1.68%
Free cash flow per share (TTM)
-3.324
Growth
Revenue change (TTM)
54.50%
Earnings per share change (TTM)
-47.07%
3-year revenue growth (CAGR)
195.60%
10-year revenue growth (CAGR)
47.45%
3-year earnings per share growth (CAGR)
-13.38%
10-year earnings per share growth (CAGR)
14.37%
What the Analysts think about Ascendis Pharma
Analyst ratings (Buy, Hold, Sell) for Ascendis Pharma stock.
Bulls say / Bears say
Ascendis Pharma’s Q2 2025 revenue surged 339% year-over-year to €158.05 million, beating consensus forecasts and narrowing its loss to €0.82 per share, driven by robust sales of YORVIPATH and SKYTROFA (Investing.com)
The FDA accepted the New Drug Application for TransCon CNP under Priority Review with a PDUFA action date of November 30, 2025, positioning Ascendis to potentially secure a third approved therapy this year (Investing.com)
A pooled analysis presented at Kidney Week 2025 demonstrated that TransCon PTH delivers sustained eGFR improvements over three years in adults with hypoparathyroidism, reinforcing its long-term renoprotective benefits (Investing.com)
Ascendis reported a Q2 net loss of €38.9 million (€0.82 per share), underlining persistent unprofitability and dependence on external financing to fund operations (Investing.com)
Selling, general, and administrative expenses rose by 44.8% year-over-year to €107.6 million in Q2 2025, outstripping the 13.8% reduction in R&D costs and exerting margin pressure (Ainvest)
For the first half of 2025, Ascendis posted a net loss of €133.5 million despite revenue rising to €258.9 million, with elevated R&D and SG&A spending potentially weighing on investor confidence (TipRanks)
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
Ascendis Pharma Financial Performance
Revenues and expenses
Ascendis Pharma Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ascendis Pharma stock?
Ascendis Pharma (ASND) has a market cap of $12B as of November 09, 2025.
What is the P/E ratio for Ascendis Pharma stock?
The price to earnings (P/E) ratio for Ascendis Pharma (ASND) stock is 0 as of November 09, 2025.
Does Ascendis Pharma stock pay dividends?
No, Ascendis Pharma (ASND) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Ascendis Pharma dividend payment date?
Ascendis Pharma (ASND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ascendis Pharma?
Ascendis Pharma (ASND) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.